Who
Patrick A. Mayes
EVP & Chief Scientific Officer
Company insider
Files Form 4 as: EVP & Chief Scientific Officer, Incyte.
In numbers
- Trades disclosed
- 111
- Buys
- 0
- Sells
- 5
- Bought
- $0
- Sold
- $12.6M
- Companies
- 1
- Companies where not an officer
- 0
- First trade
- 1 Oct 2025
- Last trade
- 5 Aug 2026
- Last filed
- 7 Aug 2026
Companies traded
Activity over time
1 Dec 2025 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 5 Aug 2026filed 7 Aug 2026 | INCY IncyteLife-science tools | SEC FORM 4 Code M | $235K2,207 at $106.47 | filing |
| 5 Aug 2026filed 7 Aug 2026 | INCY IncyteLife-science tools | SEC FORM 4 Sold | $274K2,207 at $123.99 | filing |
| 5 Aug 2026filed 7 Aug 2026 | INCY Incyteoption or derivative · Life-science tools | SEC FORM 4 Code M | —2,207 at $0.00 | filing |
| 5 Aug 2026filed 7 Aug 2026 | INCY Incyteoption or derivative · Life-science tools | SEC FORM 4 Code M | —2,207 at $0.00 | filing |
| 5 Aug 2026filed 7 Aug 2026 | INCY IncyteLife-science tools | SEC FORM 4 Code M | $235K2,207 at $106.47 | filing |
| 5 Aug 2026filed 7 Aug 2026 | INCY IncyteLife-science tools | SEC FORM 4 Sold | $274K2,207 at $123.99 | filing |
| 3 Aug 2026filed 4 Aug 2026 | INCY IncyteLife-science tools | SEC FORM 4 Code M | $638K6,055 at $105.43 | filing |
| 3 Aug 2026filed 4 Aug 2026 | INCY IncyteLife-science tools | SEC FORM 4 Sold | $729K6,055 at $120.43 | filing |
| 3 Aug 2026filed 4 Aug 2026 | INCY Incyteoption or derivative · Life-science tools | SEC FORM 4 Code M | —6,055 at $0.00 | filing |
| 3 Aug 2026filed 4 Aug 2026 | INCY Incyteoption or derivative · Life-science tools | SEC FORM 4 Code M | —6,055 at $0.00 | filing |
| 3 Aug 2026filed 4 Aug 2026 | INCY IncyteLife-science tools | SEC FORM 4 Code M | $638K6,055 at $105.43 | filing |
| 3 Aug 2026filed 4 Aug 2026 | INCY IncyteLife-science tools | SEC FORM 4 Sold | $729K6,055 at $120.43 | filing |
| 31 Jul 2026filed 4 Aug 2026 | INCY IncyteLife-science tools | SEC FORM 4 Code M | $179K2,918 at $61.18 | filing |
| 31 Jul 2026filed 4 Aug 2026 | INCY IncyteLife-science tools | SEC FORM 4 Code M | $252K3,023 at $83.20 | filing |
| 31 Jul 2026filed 4 Aug 2026 | INCY IncyteLife-science tools | SEC FORM 4 Code M | $219K2,623 at $83.58 | filing |
| 31 Jul 2026filed 4 Aug 2026 | INCY IncyteLife-science tools | SEC FORM 4 Code M | $140K1,642 at $85.01 | filing |
| 31 Jul 2026filed 4 Aug 2026 | INCY IncyteLife-science tools | SEC FORM 4 Code M | $208K2,293 at $90.56 | filing |
| 31 Jul 2026filed 4 Aug 2026 | INCY IncyteLife-science tools | SEC FORM 4 Code M | $9,05085 at $106.47 | filing |
| 31 Jul 2026filed 4 Aug 2026 | INCY IncyteLife-science tools | SEC FORM 4 Code M | $34K326 at $105.43 | filing |
| 31 Jul 2026filed 4 Aug 2026 | INCY IncyteLife-science tools | SEC FORM 4 Sold | $1.8M14,661 at $119.46 | filing |
News
Comparing Madrigal Pharmaceuticals (NASDAQ:MDGL) and Incyte (NASDAQ:INCY)INCY · themarketsdaily.com · 20 Oct 2026
0 headlines in the last 90 days name Patrick A. Mayes; 1 article from the last 14 days about the 1 company they traded most, at most three about any one of them.